Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, ...

A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications ...

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help ...

Colorado drugmaker Ambrosia Biosciences has landed $100 million to pursue an oral obesity drug it’s hoping can compete with a ...

Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator ...

The company, led by Ron Renaud, raised $1 billion in venture funding to develop a competitor to Wegovy and Zepbound that’s ...

Foundayo could erase the Wegovy pill’s four-month head start as the two drugmakers clash on a debate of efficacy and ...

Though the therapy, Kresladi, isn’t seen as a big seller, its clearance is a step forward for a company that’s lost most of ...

The buyout, which includes another $525 million in floated payouts, hands Otsuka a medicine it sees as a possibly ...

The deal secures two sleep disorder drugs that would fill a hole in the company’s portfolio and intensify a competition with ...

It's the biggest life sciences private fund ever raised, coming in nearly 40% larger than its Blackstone predecessor vehicle.

Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, ...